The Conversation (0)
Record Quarterly Revenue of $149.3 Million, a 10.6% Increase Year-Over-Year
GAAP Earnings Per Share of $0.37, Non-GAAP Earnings Per Share of $0.60
Raising Full Year 2026 Revenue Growth Guidance from 6% - 8% to 8% - 10%
Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE: PRLB), the world's leading provider of digital manufacturing services, today announced financial results for the second quarter ended June 30, 2026.
Second Quarter 2026 Financial Highlights :
- Revenue was a record $149.3 million, a 10.6% increase over the second quarter of 2025.
- Total revenue per customer contact increased 16.7% year-over-year.
- CNC machining revenue grew 13.6% year-over-year.
- Injection molding revenue grew 13.1% year-over-year.
- GAAP gross margin was 46.4%, up from 44.3% in the second quarter of 2025. Non-GAAP gross margin was 46.8%, up 200 bps from 44.8% in the second quarter of 2025.
- GAAP operating margin was 7.6%, up from 3.7% in the second quarter of 2025. Non-GAAP operating margin was 12.0%, up 340 bps from 8.6% in the second quarter of 2025.
- GAAP net income was $0.37 per diluted share, compared to $0.18 per diluted share in the second quarter of 2025. Non-GAAP net income was $0.60 per diluted share, compared to $0.41 per diluted share in the second quarter of 2025.
Note: See "Non-GAAP Financial Measures" below.
"We delivered another strong quarter with record revenue, double-digit revenue growth, and both gross and operating margin expansion. More importantly, we are seeing increasing evidence that our strategy is gaining traction across the business, with larger strategic customers expanding their relationships with Protolabs," said President and Chief Executive Officer Suresh Krishna. "Through the first half of 2026, we have demonstrated that Protolabs can deliver strong financial performance while simultaneously transforming the business for the future. We are encouraged by the momentum we are seeing across customers, services, and regions."
Additional Second Quarter 2026 Financial Highlights :
- Adjusted EBITDA was $25.1 million, or 16.8% of revenue, compared to $19.7 million, or 14.6% of revenue, in the second quarter of 2025. See "Non-GAAP Financial Measures" below.
- Cash generated from operations was $15.4 million.
- Cash and investments balance was $162.9 million as of June 30, 2026.
"Record revenue and meaningful margin expansion in the second quarter highlight the strength and scalability of our business model," said Chief Financial Officer Dan Schumacher. "We continue to generate strong cash flow while investing in strategic growth initiatives, and we remain focused on balancing profitable growth with disciplined execution to drive value for customers and shareholders."
Financial Guidance and Outlook:
- For full year 2026, Protolabs is raising its guidance and now expects to generate revenue growth between 8% and 10%.
- For the third quarter of 2026, the Company expects revenue between $145.0 million and $153.0 million.
- For the third quarter of 2026, the Company expects GAAP diluted net income per share between $0.34 and $0.42, and non-GAAP diluted net income per share between $0.56 and $0.64. See "Non-GAAP Financial Measures" below.
Non-GAAP Financial Measures
The Company has included non-GAAP revenue growth by region and by product line that excludes the impact of changes in foreign currency exchange rates (collectively, "non-GAAP revenue growth"). Management believes these metrics, when viewed in conjunction with the comparable GAAP metrics, are useful in evaluating the underlying business trends and ongoing operating performance of the Company.
The Company has included earnings before interest, taxes, depreciation and amortization ("EBITDA") and EBITDA, adjusted for stock-based compensation expense, unrealized loss (gain) on foreign currency, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs (collectively, "Adjusted EBITDA"), in this press release to provide investors with additional information regarding the Company's financial results. The Company has also included earnings before interest, taxes, depreciation and amortization margin ("EBITDA margin") and EBITDA margin, adjusted for stock-based compensation expense, unrealized loss (gain) on foreign currency, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs (collectively, "Adjusted EBITDA margin"), in this press release to provide investors with additional information regarding the Company's financial results.
The Company has included non-GAAP gross margin, adjusted for stock-based compensation expense, amortization expense and trade refunds and charges, net, in this press release to provide investors with additional information regarding the Company's financial results.
The Company has included non-GAAP operating margin, adjusted for stock-based compensation expense, amortization expense, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs (collectively, "non-GAAP operating margin"), in this press release to provide investors with additional information regarding the Company's financial results.
The Company has included non-GAAP net income and non-GAAP net income per share, in each case, adjusted for stock-based compensation expense, amortization expense, unrealized loss (gain) on foreign currency, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs (collectively, "non-GAAP net income"), in this press release to provide investors with additional information regarding the Company's financial results.
The Company has provided below reconciliations of GAAP to non-GAAP net income, non-GAAP net income per share, non-GAAP gross margin, non-GAAP operating margin, non-GAAP revenue growth by region and by product line, and Adjusted EBITDA and Adjusted EBITDA margin, the most directly comparable measures calculated and presented in accordance with GAAP. These non-GAAP measures are used by the Company's management and board of directors to understand and evaluate operating performance and trends, provide useful measures for period-to-period comparisons of the Company's business, and in determining executive and senior management incentive compensation. Accordingly, the Company believes that these non-GAAP measures provide useful information to investors and others in understanding and evaluating operating results in the same manner as our management and board of directors. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP. These non-GAAP financial measures exclude significant expenses and income that are required by GAAP to be recorded in our condensed consolidated financial statements and are subject to inherent limitations. Investors should review the reconciliations of non-GAAP financial measures to the comparable GAAP financial measures that are included in this press release.
Conference Call
The Company has scheduled a conference call to discuss its second quarter 2026 financial results and third quarter 2026 outlook today, July 31, 2026, at 8:30 a.m. EDT. To access the call in the U.S., please dial 877-709-8150 or outside the U.S. dial 201-689-8354 at least five minutes prior to the 8:30 a.m. EDT start time. No participant code is required. A simultaneous webcast of the call and accompanying presentation will be available via the investor relations section of the Protolabs website and the following link: https://edge.media-server.com/mmc/p/9bgsjeh5/ . A replay will be available for 14 days following the call on the investor relations section of the Protolabs website.
About Protolabs
Protolabs is the world's fastest manufacturing service enabling companies across every industry to streamline production of quality parts throughout the entire product life cycle. From custom prototyping to end-use production, we support product developers, engineers, and supply chain teams along every phase of their manufacturing journey. Get started now at protolabs.com .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical or current facts are "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Protolabs to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in the "Risk Factors" section within reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on Protolabs' future results. The forward-looking statements included in this press release are made only as of the date hereof. Protolabs cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Protolabs expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.
| Proto Labs, Inc. | |||||
| Condensed Consolidated Balance Sheets | |||||
| (In thousands) | |||||
|
|
|
|
| ||
|
| June 30, |
| December 31, | ||
|
| (Unaudited) |
|
| ||
| Assets |
|
|
| ||
| Current assets |
|
|
| ||
| Cash and cash equivalents | $ | 127,918 |
| $ | 110,826 |
| Short-term marketable securities |
| 14,858 |
|
| 17,297 |
| Accounts receivable, net |
| 95,074 |
|
| 78,962 |
| Inventory |
| 15,413 |
|
| 14,401 |
| Prepaid expenses and other current assets |
| 11,590 |
|
| 9,590 |
| Income taxes receivable |
| 1,390 |
|
| 2,465 |
| Total current assets |
| 266,243 |
|
| 233,541 |
|
|
|
|
| ||
| Property and equipment, net |
| 208,329 |
|
| 215,261 |
| Goodwill |
| 273,991 |
|
| 273,991 |
| Other intangible assets, net |
| 16,606 |
|
| 18,612 |
| Long-term marketable securities |
| 20,120 |
|
| 14,308 |
| Operating lease assets |
| 1,263 |
|
| 2,836 |
| Finance lease assets |
| 290 |
|
| 424 |
| Other long-term assets |
| 4,456 |
|
| 4,442 |
| Total assets | $ | 791,298 |
| $ | 763,415 |
|
|
|
|
| ||
| Liabilities and shareholders' equity |
|
|
| ||
| Current liabilities |
|
|
| ||
| Accounts payable | $ | 21,542 |
| $ | 15,104 |
| Accrued compensation |
| 18,830 |
|
| 23,674 |
| Accrued liabilities and other |
| 31,776 |
|
| 26,783 |
| Current operating lease liabilities |
| 929 |
|
| 1,155 |
| Current finance lease liabilities |
| 127 |
|
| 286 |
| Total current liabilities |
| 73,204 |
|
| 67,002 |
|
|
|
|
| ||
| Long-term operating lease liabilities |
| 1,185 |
|
| 1,606 |
| Long-term deferred tax liabilities |
| 20,625 |
|
| 16,598 |
| Other long-term liabilities |
| 4,551 |
|
| 4,277 |
|
|
|
|
| ||
| Shareholders' equity |
| 691,733 |
|
| 673,932 |
| Total liabilities and shareholders' equity | $ | 791,298 |
| $ | 763,415 |
|
|
|
|
| ||
|
|
|
|
| ||
| Proto Labs, Inc. | |||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||
| (In thousands, except share and per share amounts) | |||||||||||
| (Unaudited) | |||||||||||
|
|
|
|
|
|
|
|
| ||||
|
| Three Months Ended |
| Six Months Ended | ||||||||
|
| 2026 |
| 2025 |
| 2026 |
| 2025 | ||||
| Revenue |
|
|
|
|
|
|
| ||||
| Injection Molding | $ | 53,625 |
| $ | 47,415 |
| $ | 104,693 |
| $ | 96,138 |
| CNC Machining |
| 70,360 |
|
| 61,945 |
|
| 133,605 |
|
| 114,788 |
|
| 20,667 |
|
| 21,215 |
|
| 41,132 |
|
| 41,409 | |
| Sheet Metal |
| 4,462 |
|
| 4,303 |
|
| 8,813 |
|
| 8,514 |
| Other Revenue |
| 227 |
|
| 185 |
|
| 434 |
|
| 419 |
| Total revenue |
| 149,341 |
|
| 135,063 |
|
| 288,677 |
|
| 261,268 |
|
|
|
|
|
|
|
|
| ||||
| Cost of revenue |
| 79,999 |
|
| 75,289 |
|
| 155,743 |
|
| 145,796 |
| Gross profit |
| 69,342 |
|
| 59,774 |
|
| 132,934 |
|
| 115,472 |
|
|
|
|
|
|
|
|
| ||||
| Operating expenses |
|
|
|
|
|
|
| ||||
| Marketing and sales |
| 25,682 |
|
| 24,731 |
|
| 50,462 |
|
| 48,480 |
| Research and development |
| 10,791 |
|
| 11,173 |
|
| 21,331 |
|
| 21,782 |
| General and administrative |
| 19,650 |
|
| 18,752 |
|
| 36,662 |
|
| 35,600 |
| Restructuring and transformation costs |
| 924 |
|
| — |
|
| 2,345 |
|
| — |
| Costs related to exit and disposal activities |
| 937 |
|
| 149 |
|
| 937 |
|
| 110 |
| Total operating expenses |
| 57,984 |
|
| 54,805 |
|
| 111,737 |
|
| 105,972 |
| Income from operations |
| 11,358 |
|
| 4,969 |
|
| 21,197 |
|
| 9,500 |
| Other income, net |
| 1,245 |
|
| 1,705 |
|
| 2,723 |
|
| 3,159 |
| Income before income taxes |
| 12,603 |
|
| 6,674 |
|
| 23,920 |
|
| 12,659 |
| Provision for income taxes |
| 3,451 |
|
| 2,247 |
|
| 6,657 |
|
| 4,633 |
| Net income | $ | 9,152 |
| $ | 4,427 |
| $ | 17,263 |
| $ | 8,026 |
|
|
|
|
|
|
|
|
| ||||
| Net income per share: |
|
|
|
|
|
|
| ||||
| Basic | $ | 0.38 |
| $ | 0.19 |
| $ | 0.72 |
| $ | 0.33 |
| Diluted | $ | 0.37 |
| $ | 0.18 |
| $ | 0.71 |
| $ | 0.33 |
|
|
|
|
|
|
|
|
| ||||
| Shares used to compute net income per share: |
|
|
|
|
|
|
| ||||
| Basic |
| 23,969,254 |
|
| 23,900,390 |
|
| 23,902,802 |
|
| 24,018,119 |
| Diluted |
| 24,415,788 |
|
| 24,101,592 |
|
| 24,358,568 |
|
| 24,291,246 |
|
|
|
|
|
|
|
|
| ||||
| Proto Labs, Inc. | |||||||
| Condensed Consolidated Statements of Cash Flows | |||||||
| (In thousands) | |||||||
| (Unaudited) | |||||||
|
|
|
|
| ||||
|
| Six Months Ended | ||||||
|
|
| 2026 |
|
|
| 2025 |
|
| Operating activities |
|
|
| ||||
| Net income | $ | 17,263 |
|
| $ | 8,026 |
|
| Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
| ||||
| Depreciation and amortization |
| 16,161 |
|
|
| 17,264 |
|
| Stock-based compensation expense |
| 7,307 |
|
|
| 8,251 |
|
| Deferred taxes |
| 4,054 |
|
|
| (3,985 | ) |
| Interest on finance lease obligations |
| 5 |
|
|
| 11 |
|
| Loss on impairment of equipment |
| 186 |
|
|
| — |
|
| Impairments related to exit and closure of facilities |
| 937 |
|
|
| 448 |
|
| Gain on disposal of property and equipment |
| (120 | ) |
|
| — |
|
| Other |
| (152 | ) |
|
| (82 | ) |
| Changes in operating assets and liabilities |
| (12,663 | ) |
|
| (970 | ) |
| Net cash provided by operating activities |
| 32,978 |
|
|
| 28,963 |
|
|
|
|
|
| ||||
| Investing activities |
|
|
| ||||
| Purchases of property, equipment and other capital assets |
| (9,743 | ) |
|
| (2,730 | ) |
| Proceeds from sales of property, equipment and other capital assets |
| 1,279 |
|
|
| — |
|
| Purchases of marketable securities |
| (16,007 | ) |
|
| (11,052 | ) |
| Proceeds from maturities of marketable securities |
| 12,500 |
|
|
| 10,230 |
|
| Net cash used in investing activities |
| (11,971 | ) |
|
| (3,552 | ) |
|
|
|
|
| ||||
| Financing activities |
|
|
| ||||
| Proceeds from issuance of common stock from equity plans |
| 7,265 |
|
|
| 2,081 |
|
| Purchases of shares withheld for tax obligations |
| (5,951 | ) |
|
| (3,117 | ) |
| Repurchases of common stock |
| (5,036 | ) |
|
| (23,980 | ) |
| Principal repayments of finance lease obligations |
| (160 | ) |
|
| (153 | ) |
| Net cash used in financing activities |
| (3,882 | ) |
|
| (25,169 | ) |
| Effect of exchange rate changes on cash and cash equivalents |
| (33 | ) |
|
| 1,069 |
|
| Net increase in cash and cash equivalents |
| 17,092 |
|
|
| 1,311 |
|
| Cash and cash equivalents, beginning of period |
| 110,826 |
|
|
| 89,071 |
|
| Cash and cash equivalents, end of period | $ | 127,918 |
|
| $ | 90,382 |
|
|
|
|
|
| ||||
| Proto Labs, Inc. | |||||||||||||||
| Reconciliation of GAAP to Non-GAAP Net Income and Non-GAAP Net Income per Share | |||||||||||||||
| (In thousands, except share and per share amounts) | |||||||||||||||
| (Unaudited) | |||||||||||||||
|
|
|
|
|
|
|
|
| ||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
| Non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized loss (gain) on foreign currency, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs |
|
|
|
|
|
|
| ||||||||
| GAAP net income | $ | 9,152 |
|
| $ | 4,427 |
|
| $ | 17,263 |
|
| $ | 8,026 |
|
| Add back: |
|
|
|
|
|
|
| ||||||||
| Stock-based compensation expense |
| 4,088 |
|
|
| 4,259 |
|
|
| 7,307 |
|
|
| 8,251 |
|
| Amortization expense |
| 905 |
|
|
| 927 |
|
|
| 1,818 |
|
|
| 1,835 |
|
| Unrealized loss (gain) on foreign currency |
| 137 |
|
|
| (179 | ) |
|
| 137 |
|
|
| (314 | ) |
| Trade refunds and charges, net |
| (327 | ) |
|
| — |
|
|
| (327 | ) |
|
| — |
|
| Restructuring and transformation costs |
| 924 |
|
|
| — |
|
|
| 2,345 |
|
|
| — |
|
| Costs related to exit and disposal activities |
| 937 |
|
|
| 149 |
|
|
| 937 |
|
|
| 110 |
|
| CEO transition costs |
| — |
|
|
| 1,362 |
|
|
| — |
|
|
| 1,362 |
|
| Total adjustments 1 |
| 6,664 |
|
|
| 6,518 |
|
|
| 12,217 |
|
|
| 11,244 |
|
| Income tax benefits on adjustments 2 |
| (1,111 | ) |
|
| (958 | ) |
|
| (1,697 | ) |
|
| (1,200 | ) |
| Non-GAAP net income | $ | 14,705 |
|
| $ | 9,987 |
|
| $ | 27,783 |
|
| $ | 18,070 |
|
|
|
|
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
| ||||||||
| Non-GAAP net income per share: |
|
|
|
|
|
|
| ||||||||
| Basic | $ | 0.61 |
|
| $ | 0.42 |
|
| $ | 1.16 |
|
| $ | 0.75 |
|
| Diluted | $ | 0.60 |
|
| $ | 0.41 |
|
| $ | 1.14 |
|
| $ | 0.74 |
|
|
|
|
|
|
|
|
|
| ||||||||
| Shares used to compute non-GAAP net income per share: |
|
|
|
|
|
|
| ||||||||
| Basic |
| 23,969,254 |
|
|
| 23,900,390 |
|
|
| 23,902,802 |
|
|
| 24,018,119 |
|
| Diluted |
| 24,415,788 |
|
|
| 24,101,592 |
|
|
| 24,358,568 |
|
|
| 24,291,246 |
|
|
|
|
|
|
|
|
|
| ||||||||
| 1 Stock-based compensation expense, amortization expense, unrealized loss (gain) on foreign currency, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs were included in the following GAAP consolidated statement of operations categories: |
|
| Three Months Ended |
| Six Months Ended | ||||||||||
|
| 2026 |
|
| 2025 |
|
| 2026 |
|
| 2025 |
| ||
|
|
|
|
|
|
|
|
| ||||||
| Cost of revenue | $ | 549 |
| $ | 767 |
|
| $ | 1,285 |
| $ | 1,569 |
|
|
|
|
|
|
|
|
|
| ||||||
| Marketing and sales |
| 819 |
|
| 808 |
|
|
| 1,524 |
|
| 1,586 |
|
| Research and development |
| 641 |
|
| 735 |
|
|
| 1,069 |
|
| 1,360 |
|
| General and administrative |
| 2,657 |
|
| 4,238 |
|
|
| 4,920 |
|
| 6,933 |
|
| Restructuring and transformation costs |
| 924 |
|
| — |
|
|
| 2,345 |
|
| — |
|
| Costs related to exit and disposal activities |
| 937 |
|
| 149 |
|
|
| 937 |
|
| 110 |
|
| Total operating expenses |
| 5,978 |
|
| 5,930 |
|
|
| 10,795 |
|
| 9,989 |
|
|
|
|
|
|
|
|
|
| ||||||
| Other income, net |
| 137 |
|
| (179 | ) |
|
| 137 |
|
| (314 | ) |
| Total adjustments | $ | 6,664 |
| $ | 6,518 |
|
| $ | 12,217 |
| $ | 11,244 |
|
|
|
|
|
|
|
|
|
| ||||||
| 2 For the three and six months ended June 30, 2026 and 2025, income tax effects were calculated using the effective tax rate for the relevant jurisdictions. The Company's non-GAAP tax rates differ from its GAAP tax rates due primarily to the mix of activity incurred in domestic and foreign tax jurisdictions and removing effective tax rate benefits from stock-based compensation activity in the respective period. |
|
|
| Proto Labs, Inc. | |||||||||||||||
| Reconciliation of GAAP to Non-GAAP Gross Margin | |||||||||||||||
| (In thousands) | |||||||||||||||
| (Unaudited) | |||||||||||||||
|
|
|
|
|
|
|
|
| ||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
| Revenue | $ | 149,341 |
|
| $ | 135,063 |
|
| $ | 288,677 |
|
| $ | 261,268 |
|
| Gross profit |
| 69,342 |
|
|
| 59,774 |
|
|
| 132,934 |
|
|
| 115,472 |
|
| GAAP gross margin |
| 46.4 | % |
|
| 44.3 | % |
|
| 46.0 | % |
|
| 44.2 | % |
| Add back: |
|
|
|
|
|
|
| ||||||||
| Stock-based compensation expense |
| 534 |
|
|
| 424 |
|
|
| 928 |
|
|
| 884 |
|
| Amortization expense |
| 342 |
|
|
| 343 |
|
|
| 684 |
|
|
| 685 |
|
| Trade refunds and charges, net |
| (327 | ) |
|
| — |
|
|
| (327 | ) |
|
| — |
|
| Total adjustments |
| 549 |
|
|
| 767 |
|
|
| 1,285 |
|
|
| 1,569 |
|
| Non-GAAP gross profit | $ | 69,891 |
|
| $ | 60,541 |
|
| $ | 134,219 |
|
| $ | 117,041 |
|
| Non-GAAP gross margin |
| 46.8 | % |
|
| 44.8 | % |
|
| 46.5 | % |
|
| 44.8 | % |
|
|
|
|
|
|
|
|
| ||||||||
| Proto Labs, Inc. | |||||||||||||||
| Reconciliation of GAAP to Non-GAAP Operating Margin | |||||||||||||||
| (In thousands) | |||||||||||||||
| (Unaudited) | |||||||||||||||
|
|
|
|
|
|
|
|
| ||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
| Revenue | $ | 149,341 |
|
| $ | 135,063 |
|
| $ | 288,677 |
|
| $ | 261,268 |
|
| Income from operations |
| 11,358 |
|
|
| 4,969 |
|
|
| 21,197 |
|
|
| 9,500 |
|
| GAAP operating margin |
| 7.6 | % |
|
| 3.7 | % |
|
| 7.3 | % |
|
| 3.6 | % |
| Add back: |
|
|
|
|
|
|
| ||||||||
| Stock-based compensation expense |
| 4,088 |
|
|
| 4,259 |
|
|
| 7,307 |
|
|
| 8,251 |
|
| Amortization expense |
| 905 |
|
|
| 927 |
|
|
| 1,818 |
|
|
| 1,835 |
|
| Trade refunds and charges, net |
| (327 | ) |
|
| — |
|
|
| (327 | ) |
|
| — |
|
| Restructuring and transformation costs |
| 924 |
|
|
| — |
|
|
| 2,345 |
|
|
| — |
|
| Costs related to exit and disposal activities |
| 937 |
|
|
| 149 |
|
|
| 937 |
|
|
| 110 |
|
| CEO transition costs |
| — |
|
|
| 1,362 |
|
|
| — |
|
|
| 1,362 |
|
| Total adjustments |
| 6,527 |
|
|
| 6,697 |
|
|
| 12,080 |
|
|
| 11,558 |
|
| Non-GAAP income from operations | $ | 17,885 |
|
| $ | 11,666 |
|
| $ | 33,277 |
|
| $ | 21,058 |
|
| Non-GAAP operating margin |
| 12.0 | % |
|
| 8.6 | % |
|
| 11.5 | % |
|
| 8.1 | % |
|
|
|
|
|
|
|
|
| ||||||||
| Proto Labs, Inc. | |||||||||||||||
| Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA | |||||||||||||||
| (In thousands) | |||||||||||||||
| (Unaudited) | |||||||||||||||
|
|
|
|
|
|
|
|
| ||||||||
|
| Three Months Ended |
| Six Months Ended | ||||||||||||
|
|
| 2026 |
|
|
| 2025 |
|
|
| 2026 |
|
|
| 2025 |
|
| Revenue | $ | 149,341 |
|
| $ | 135,063 |
|
| $ | 288,677 |
|
| $ | 261,268 |
|
| GAAP net income |
| 9,152 |
|
|
| 4,427 |
|
|
| 17,263 |
|
|
| 8,026 |
|
| GAAP net income margin |
| 6.1 | % |
|
| 3.3 | % |
|
| 6.0 | % |
|
| 3.1 | % |
| Add back: |
|
|
|
|
|
|
| ||||||||
| Amortization expense | $ | 905 |
|
| $ | 927 |
|
| $ | 1,818 |
|
| $ | 1,835 |
|
| Depreciation expense |
| 7,183 |
|
|
| 7,643 |
|
|
| 14,343 |
|
|
| 15,429 |
|
| Interest income, net |
| (1,331 | ) |
|
| (1,143 | ) |
|
| (2,584 | ) |
|
| (2,251 | ) |
| Provision for income taxes |
| 3,451 |
|
|
| 2,247 |
|
|
| 6,657 |
|
|
| 4,633 |
|
| EBITDA |
| 19,360 |
|
|
| 14,101 |
|
|
| 37,497 |
|
|
| 27,672 |
|
| EBITDA Margin |
| 13.0 | % |
|
| 10.4 | % |
|
| 13.0 | % |
|
| 10.6 | % |
| Add back: |
|
|
|
|
|
|
| ||||||||
| Stock-based compensation expense |
| 4,088 |
|
|
| 4,259 |
|
|
| 7,307 |
|
|
| 8,251 |
|
| Unrealized loss (gain) on foreign currency |
| 137 |
|
|
| (179 | ) |
|
| 137 |
|
|
| (314 | ) |
| Trade refunds and charges, net |
| (327 | ) |
|
| — |
|
|
| (327 | ) |
|
| — |
|
| Restructuring and transformation costs |
| 924 |
|
|
| — |
|
|
| 2,345 |
|
|
| — |
|
| Costs related to exit and disposal activities |
| 937 |
|
|
| 149 |
|
|
| 937 |
|
|
| 110 |
|
| CEO transition costs |
| — |
|
|
| 1,362 |
|
|
| — |
|
|
| 1,362 |
|
| Total adjustments |
| 5,759 |
|
|
| 5,591 |
|
|
| 10,399 |
|
|
| 9,409 |
|
| Adjusted EBITDA | $ | 25,119 |
|
| $ | 19,692 |
|
| $ | 47,896 |
|
| $ | 37,081 |
|
| Adjusted EBITDA Margin |
| 16.8 | % |
|
| 14.6 | % |
|
| 16.6 | % |
|
| 14.2 | % |
|
|
|
|
|
|
|
|
| ||||||||
| Proto Labs, Inc. | ||||||||||||||||||
| Comparison of GAAP to Non-GAAP Revenue Growth by Region | ||||||||||||||||||
| (In thousands) | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
| Three Months Ended |
| Three Months Ended |
| % Change 2 |
| % Change Organic 3 | |||||||||||
|
| GAAP |
| Foreign Currency 1 |
| Non-GAAP |
| GAAP |
|
| |||||||||
| Revenues |
|
|
|
|
|
|
|
|
|
|
| |||||||
| United States | $ | 122,759 |
| $ | — |
|
| $ | 122,759 |
| $ | 110,712 |
| 10.9 | % |
| 10.9 | % |
| Europe |
| 26,582 |
|
| (447 | ) |
|
| 26,135 |
|
| 24,351 |
| 9.2 |
|
| 7.3 |
|
| Total revenue | $ | 149,341 |
| $ | (447 | ) |
| $ | 148,894 |
| $ | 135,063 |
| 10.6 | % |
| 10.2 | % |
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
| Six Months Ended |
| Six Months Ended |
| % Change 2 |
| % Change Organic 3 | |||||||||||
|
| GAAP |
| Foreign Currency 1 |
| Non-GAAP |
| GAAP |
|
| |||||||||
| Revenues |
|
|
|
|
|
|
|
|
|
|
| |||||||
| United States | $ | 234,886 |
| $ | — |
|
| $ | 234,886 |
| $ | 210,979 |
| 11.3 | % |
| 11.3 | % |
| Europe |
| 53,791 |
|
| (2,604 | ) |
|
| 51,187 |
|
| 50,289 |
| 7.0 |
|
| 1.8 |
|
| Total revenue | $ | 288,677 |
| $ | (2,604 | ) |
| $ | 286,073 |
| $ | 261,268 |
| 10.5 | % |
| 9.5 | % |
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
| 1 Revenue for the three and six months ended June 30, 2026 has been recalculated using 2025 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates. |
| 2 This column presents the percentage change from GAAP revenue for the three and six months ended June 30, 2025 to GAAP revenue for the three and six months ended June 30, 2026. |
| 3 This column presents the percentage change from GAAP revenue for the three and six months ended June 30, 2025 to non-GAAP revenue for the three and six months ended June 30, 2026 (as recalculated using the foreign currency exchange rates in effect during the three and six months ended June 30, 2025) in order to provide a constant-currency comparison. |
|
|
| Proto Labs, Inc. | ||||||||||||||||||
| Comparison of GAAP to Non-GAAP Revenue Growth by Product Line | ||||||||||||||||||
| (In thousands) | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
| Three Months Ended |
| Three Months Ended |
| % Change 2 |
| % Change Organic 3 | |||||||||||
|
| GAAP |
| Foreign Currency 1 |
| Non-GAAP |
| GAAP |
|
| |||||||||
| Revenues |
|
|
|
|
|
|
|
|
|
|
| |||||||
| Injection Molding | $ | 53,625 |
| $ | (89 | ) |
| $ | 53,536 |
| $ | 47,415 |
| 13.1 | % |
| 12.9 | % |
| CNC Machining |
| 70,360 |
|
| (318 | ) |
|
| 70,042 |
|
| 61,945 |
| 13.6 |
|
| 13.1 |
|
| 3D Printing |
| 20,667 |
|
| (30 | ) |
|
| 20,637 |
|
| 21,215 |
| (2.6 | ) |
| (2.7 | ) |
| Sheet Metal |
| 4,462 |
|
| (8 | ) |
|
| 4,454 |
|
| 4,303 |
| 3.7 |
|
| 3.5 |
|
| Other Revenue |
| 227 |
|
| (2 | ) |
|
| 225 |
|
| 185 |
| 22.7 |
|
| 21.6 |
|
| Total revenue | $ | 149,341 |
| $ | (447 | ) |
| $ | 148,894 |
| $ | 135,063 |
| 10.6 | % |
| 10.2 | % |
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
|
| Six Months Ended |
| Six Months Ended |
| % Change 2 |
| % Change Organic 3 | |||||||||||
|
| GAAP |
| Foreign Currency 1 |
| Non-GAAP |
| GAAP |
|
| |||||||||
| Revenues |
|
|
|
|
|
|
|
|
|
|
| |||||||
| Injection Molding | $ | 104,693 |
| $ | (720 | ) |
| $ | 103,973 |
| $ | 96,138 |
| 8.9 | % |
| 8.1 | % |
| CNC Machining |
| 133,605 |
|
| (1,432 | ) |
|
| 132,173 |
|
| 114,788 |
| 16.4 |
|
| 15.1 |
|
| 3D Printing |
| 41,132 |
|
| (398 | ) |
|
| 40,734 |
|
| 41,409 |
| (0.7 | ) |
| (1.6 | ) |
| Sheet Metal |
| 8,813 |
|
| (50 | ) |
|
| 8,763 |
|
| 8,514 |
| 3.5 |
|
| 2.9 |
|
| Other Revenue |
| 434 |
|
| (4 | ) |
|
| 430 |
|
| 419 |
| 3.6 |
|
| 2.6 |
|
| Total revenue | $ | 288,677 |
| $ | (2,604 | ) |
| $ | 286,073 |
| $ | 261,268 |
| 10.5 | % |
| 9.5 | % |
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
| 1 Revenue for the three and six months ended June 30, 2026 has been recalculated using 2025 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates. |
| 2 This column presents the percentage change from GAAP revenue for the three and six months ended June 30, 2025 to GAAP revenue for the three and six months ended June 30, 2026. |
| 3 This column presents the percentage change from GAAP revenue for the three and six months ended June 30, 2025 to non-GAAP revenue for the three and six months ended June 30, 2026 (as recalculated using the foreign currency exchange rates in effect during the three and six months ended June 30, 2025) in order to provide a constant-currency comparison. |
| Proto Labs, Inc. | |||||||||||
| Customer Contact Information | |||||||||||
| (In thousands, except customer contacts and per customer contact amounts) | |||||||||||
| (Unaudited) | |||||||||||
|
|
|
|
|
|
|
|
| ||||
|
| Three Months Ended |
| Six Months Ended | ||||||||
|
| 2026 |
| 2025 |
| 2026 |
| 2025 | ||||
| Revenue | $ | 149,341 |
| $ | 135,063 |
| $ | 288,677 |
| $ | 261,268 |
| Customer contacts |
| 20,630 |
|
| 21,775 |
|
| 31,069 |
|
| 33,136 |
| Revenue per customer contact 1 | $ | 7,239 |
| $ | 6,203 |
| $ | 9,291 |
| $ | 7,885 |
|
|
|
|
|
|
|
|
| ||||
| 1 Revenue per customer contact is calculated using the revenue recognized during the respective period divided by the actual number of customer contacts served during the same period. Customer contacts are product developers, engineers, procurement and supply chain professionals and other individuals who place an order, and that order is shipped and invoiced during the period. The Company believes revenue per customer contact is useful to investors in evaluating the underlying business trends and ongoing operating performance of the Company. |
|
|
| Proto Labs, Inc. | |||||
| Reconciliation of GAAP to Non-GAAP Guidance | |||||
| (Unaudited) | |||||
|
|
|
|
| ||
|
| Q3 2026 Outlook | ||||
|
| Low |
| High | ||
| GAAP diluted net income per share | $ | 0.34 |
| $ | 0.42 |
| Add back: |
|
|
| ||
| Stock-based compensation expense |
| 0.19 |
|
| 0.19 |
| Amortization expense |
| 0.03 |
|
| 0.03 |
| Total adjustments |
| 0.22 |
|
| 0.22 |
| Non-GAAP diluted net income per share | $ | 0.56 |
| $ | 0.64 |
|
|
|
|
| ||
View source version on businesswire.com: https://www.businesswire.com/news/home/20260731266719/en/
Investor Relations Contacts
Protolabs
Ryan Johnsrud, 612-225-4873
Sr. Manager – Investor Relations and Corporate Development
ryan.johnsrud@protolabs.com
Gateway Group, Inc.
949-574-3860
PRLB@gateway-grp.com
Media Contact
Protolabs
Brent Renneke, 763-479-7704
Corporate Communications Manager
brent.renneke@protolabs.com
